Dual Antiplatelet Therapy (DAPT) Strategies in ACS and CCD
Definition
Dual antiplatelet therapy (DAPT) refers to the combination of aspirin and an oral P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) used to prevent recurrent atherothrombotic events following ACS or PCI. The key challenge is balancing ischemic protection (favoring longer, more potent DAPT) against bleeding risk (favoring shorter or de-escalated DAPT). Multiple RCTs have established strategies to individualize this trade-off.
Key Concepts
Default Duration: ≥12 Months
- DAPT with aspirin + oral P2Y12 inhibitor for at least 12 months as the default strategy in patients with ACS not at high bleeding risk — Class I/A. (sources/ACS-AHA-2025, rating: very high)
- CURE trial (n=12,562): clopidogrel reduced composite death/MI/stroke in NSTE-ACS vs aspirin alone consistently regardless of management strategy. (sources/ACS-AHA-2025, rating: very high)
- TRITON-TIMI 38: prasugrel reduced MACE by 19% vs clopidogrel; PLATO: ticagrelor reduced MACE by 16% vs clopidogrel — both at expense of increased non-CABG bleeding. (sources/ACS-AHA-2025, rating: very high)
P2Y12 Inhibitor Selection
| Agent | Load | Maintenance | Preferred Setting | Key Consideration |
|---|---|---|---|---|
| Ticagrelor | 180 mg | 90 mg BID | NSTE-ACS ± PCI; STEMI-PCI | Transient dyspnoea 10–15%; aspirin dose ≤100 mg |
| Prasugrel | 60 mg | 10 mg (5 mg if <60 kg or ≥75 y) | STEMI/NSTE-ACS with PCI | Contraindicated with prior stroke/TIA; avoid if age ≥75 y in most cases |
| Clopidogrel | 300–600 mg | 75 mg | STEMI + fibrinolysis; high bleeding risk; OAC patients; elderly | ~30–40% hyporesponders; preferred when OAC required |
Ticagrelor Monotherapy Strategy (Aspirin Discontinuation ≥1 Month Post-PCI)
- Class I/A: After ≥1 month of ticagrelor-based DAPT, aspirin withdrawal → ticagrelor monotherapy to reduce bleeding without excess MACE. (sources/ACS-AHA-2025, rating: very high)
- Multiple RCTs (TWILIGHT, TICO, STOP-DAPT-2 ACS, GLOBAL LEADERS): consistent reduction in bleeding; maintained ischemic protection. Individual patient data pooled analyses confirm consistent results. (sources/ACS-AHA-2025, rating: very high)
- Clopidogrel monotherapy (1–2 months post-PCI): may increase MACE vs longer DAPT in ACS patients; significant pharmacodynamic variability (30–40% hyporesponders) contributes to uncertainty — not preferred in ACS. (sources/ACS-AHA-2025, rating: very high)
- P2Y12 discontinuation followed by aspirin alone (3–6 months post-PCI): excess thrombotic risk — avoid in ACS. (sources/ACS-AHA-2025, rating: very high)
Bleeding Reduction Strategies
- Proton pump inhibitor (PPI): Class I/A for patients at high GI bleeding risk on DAPT or OAC. No pharmacodynamic interaction between PPIs and ticagrelor/prasugrel. Potential CYP2C19 interaction with omeprazole + clopidogrel (pharmacodynamic effect only; COGENT RCT showed no increase in ischemic events with omeprazole + clopidogrel). (sources/ACS-AHA-2025, rating: very high)
- De-escalation (switch from ticagrelor/prasugrel to clopidogrel after 1 month): Class IIb/B-R. Guided de-escalation (platelet function/genotyping assays) or unguided — both reduce bleeding without clear increase in ischemic events. TROPICAL-ACS, HOST-REDUCE-POLYTECH-ACS, TALOS-AMI trials. (sources/ACS-AHA-2025, rating: very high)
- Single antiplatelet therapy after 1 month (high bleeding risk patients): Class IIb/B-R. MASTER DAPT trial (high bleeding risk, post-PCI 4 weeks): abbreviated DAPT non-inferior for ischemic events; superior for bleeding. (sources/ACS-AHA-2025, rating: very high)
Academic Research Consortium High Bleeding Risk (HBR) Criteria
≥1 Major OR ≥2 Minor criteria = high bleeding risk.
Major Criteria:
- Anticipated long-term oral anticoagulation
- Severe/end-stage CKD (eGFR <30 mL/min)
- Hemoglobin <11 g/dL
- Spontaneous bleeding requiring hospitalization/transfusion in past 6 months (or recurrent)
- Thrombocytopenia (platelets <100 × 10⁹/L)
- Chronic bleeding diathesis
- Liver cirrhosis with portal hypertension
- Active malignancy within past 12 months
- Previous spontaneous ICH (ever); traumatic ICH within 12 months; brain AVM; moderate/severe ischemic stroke within 6 months
- Non-deferrable major surgery on DAPT
- Recent major surgery or major trauma within 30 days before PCI
Minor Criteria: Age ≥75 y; moderate CKD (eGFR 30–59); Hgb 11–12.9 g/dL (men) / 11–11.9 g/dL (women); spontaneous bleeding requiring hospitalization within 12 months; any ischemic stroke ever; long-term NSAIDs or steroids
Antiplatelet Therapy with Oral Anticoagulation (Triple Therapy)
- ACS patients with indication for OAC (AF, VTE, prosthetic valves): aspirin discontinuation 1–4 weeks post-PCI + continued P2Y12 inhibitor (preferably clopidogrel) + OAC — Class I/B-R. (sources/ACS-AHA-2025, rating: very high)
- Multiple RCTs (RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI, PIONEER AF-PCI): aspirin discontinuation reduces major bleeding without significant increase in stroke or overall MACE. ~80% of stent thrombosis events occur within 30 days of PCI — if high stent thrombosis risk, aspirin for up to 30 days before discontinuing. (sources/ACS-AHA-2025, rating: very high)
- DOAC preferred over VKA for most patients (except mechanical valves, rheumatic MS). (sources/ACS-AHA-2025, rating: very high)
- See entities/Atrial-Fibrillation for anticoagulation strategy in ACS + AF. (sources/ACS-AHA-2025, rating: very high)
P2Y12 Inhibitor Interruption for CABG
| Agent | Elective CABG | Urgent CABG |
|---|---|---|
| Clopidogrel | Interrupt 5 days before | Interrupt ≥24 h (ideally) |
| Prasugrel | Interrupt 7 days before | Interrupt ≥24 h (ideally) |
| Ticagrelor | Interrupt 3–5 days before | Interrupt ≥24 h (ideally) |
- Resume P2Y12 inhibitor 24–72 h after surgery when bleeding risk not excessive. (sources/ACS-AHA-2025, rating: very high)
CCD-Phase Antiplatelet Management
- Aspirin 81 mg daily (COR 1/A): Indefinite secondary prevention for CCD; 81 mg = 325 mg (ADAPTABLE n=15,076: no difference in composite death/MI/stroke; no difference in major bleeding). (sources/CCS-AHA-2023, rating: very high)
- DAPT 6 months post-PCI → SAPT (COR 1/A): Meta-analysis (n=31,666): shorter DAPT (≤6 months) — similar mortality, MI, and stent thrombosis rates but lower major bleeding vs 12-month DAPT. Aspirin continued indefinitely after P2Y12 cessation. (sources/CCS-AHA-2023, rating: very high)
- P2Y12 monotherapy after 1–3 months DAPT (COR 2a/A): SMART CHOICE, STOP-DAPT2, TWILIGHT, GLOBAL LEADERS — aspirin discontinuation after 1–3 months reduces major bleeding by 40% without increased MACE. Applies to DES populations including 35–62% stable patients. (sources/CCS-AHA-2023, rating: very high)
- Extended DAPT >12 months (up to 3 years) for prior MI, low bleeding risk (COR 2b/A): PEGASUS-TIMI 54 (n=21,162, MI 1–3 years prior): ticagrelor 60 mg BID on background aspirin — 16% reduction in CV death/MI/stroke; absolute RR 1.09% over 31 months (NNT ~91); increased major bleeding. (sources/CCS-AHA-2023, rating: very high)
- Low-dose rivaroxaban 2.5 mg BID + aspirin 81 mg (COR 2a/B-R): High ischaemic risk (multivessel CAD + DM/recurrent MI/PAD/HF/CKD) + low-moderate bleeding risk + no OAC or DAPT indication — COMPASS trial: composite CV death/stroke/MI 4.1% vs 5.4% for aspirin alone (stopped early for benefit); major bleeding 3.1% vs 1.9% (HR 1.70). Not for patients on DAPT. (sources/CCS-AHA-2023, rating: very high)
- Vorapaxar (PAR-1 inhibitor) (COR 2b/B-R): Prior MI without stroke/TIA/ICH — reduces CV death/MI/stroke; COR 3 Harm if prior stroke/TIA/ICH — increased intracranial haemorrhage. TRAP 2P-TIMI 50: 13% net clinical benefit reduction. (sources/CCS-AHA-2023, rating: very high)
- CCD + OAC (elective PCI) (COR 1/B-R): DAPT 1–4 weeks → clopidogrel + DOAC × 6 months; aspirin for ≤1 month in high thrombotic risk (COR 2a); DOAC monotherapy may be considered after 1 year post-PCI without acute indication (COR 2b/C-LD) — AFIRE: rivaroxaban monotherapy noninferior to rivaroxaban + antiplatelet in CCD + AF >1 year post-revascularisation. (sources/CCS-AHA-2023, rating: very high)
- No DAPT without ACS/PCI indication (COR 3 No Benefit/A): Clopidogrel + aspirin not better than aspirin alone for MACE in stable CCD — CHARISMA trial. (sources/CCS-AHA-2023, rating: very high)
- NSAIDs (COR 3 Harm/B-R): Coxibs, diclofenac, ibuprofen increase major vascular events (~37–70%), CV death, and HF risk; moderate-dose celecoxib may be noninferior to naproxen/ibuprofen in arthritis patients at high CV risk (PRECISION trial) but not preferred. (sources/CCS-AHA-2023, rating: very high)
Perioperative PCI Timing Before NCS
- COR 3: Harm — Elective NCS ≤30 days after PCI of any kind: Stent thrombosis risk is at its highest in the first 30 days; elective NCS requiring DAPT interruption must be deferred. (sources/periop-aha-2024, rating: very high)
- Balloon angioplasty only (no stent): NCS may proceed after ≥14 days — endothelial healing is complete without stent implantation. (sources/periop-aha-2024, rating: very high)
- DES after ACS (DES-ACS): Defer elective NCS for ≥12 months — the combination of high-thrombotic ACS substrate and new stent requires full DAPT duration before surgery. (sources/periop-aha-2024, rating: very high)
- DES after CCD (DES-CCD): Defer elective NCS for ≥6 months — lower thrombotic risk substrate permits earlier interruption compared with ACS. (sources/periop-aha-2024, rating: very high)
- Time-sensitive surgery: If NCS cannot be deferred, proceed ≥3 months post-DES with multidisciplinary discussion (surgeon + cardiologist + anaesthesiologist); accept residual stent thrombosis risk. (sources/periop-aha-2024, rating: very high)
Antiplatelet discontinuation windows before NCS:
| Agent | Elective NCS hold | Urgent NCS |
|---|---|---|
| Aspirin | 4 days (if needed) | Continue if feasible |
| Clopidogrel | 5–7 days | Ideally 24 h |
| Prasugrel | 7–10 days | Ideally 24 h |
| Ticagrelor | 3–5 days | Ideally 24 h |
- DAPT resumption: As soon as haemostasis allows; for patients with recent stent (≤12 months), early resumption (within 24–72 h) is strongly preferred to minimize stent thrombosis risk. (sources/periop-aha-2024, rating: very high)
Antiplatelet Therapy in Minor Acute Ischemic Stroke and High-Risk TIA
- DAPT for minor AIS (NIHSS 0–5) or high-risk TIA within 24h — COR 1 A:
- Loading: aspirin 325 mg + clopidogrel 300–600 mg; then aspirin 75–100 mg + clopidogrel 75 mg × 21 days → single antiplatelet monotherapy
- CHANCE trial (n=5,170, Asian cohort): 21-day DAPT reduced 90-day stroke (8.2% vs 11.7%; RRR 32%) vs aspirin alone; POINT trial (n=4,881, Western cohort): 21-day DAPT reduced 90-day MACE (6.5% vs 9.1%; RRR 25%)
- CHANCE-2: CYP2C19 ticagrelor-guided clopidogrel replacement in poor metabolisers (sources/ais-aha-2026, rating: very high)
- Ticagrelor + aspirin × 30 days for high-risk minor AIS/TIA with LAA etiology — COR 2a:
- THALES trial (n=11,016): HR 0.83 for stroke/death (5.5% vs 6.6%) vs aspirin alone; more major bleeding (0.5% vs 0.1%); benefit concentrated in LAA mechanism patients
- Not recommended for cardioembolic stroke or where OAC is indicated (sources/ais-aha-2026, rating: very high)
- Aspirin monotherapy within 24–48h of AIS (if IVT/EVT not given) — COR 1 A: IST and CAST trials (n>40,000 combined); modest (1–2%) absolute reduction in 14-day stroke/death; start within 48h of onset
- Do NOT add antiplatelet within 24h of IVT or EVT: Haemorrhagic transformation risk; IVT/EVT supersedes antiplatelet in acute window
- Duration: 21 days of DAPT → long-term single antiplatelet (aspirin 81 mg or clopidogrel 75 mg); no role for long-term DAPT after minor AIS/TIA (bleeding outweighs benefit beyond 21 days)
- See entities/Ischemic-Stroke for full AIS management framework including reperfusion and BP targets
Contradictions / Open Questions
- Optimal single antiplatelet after ticagrelor monotherapy transition: Whether long-term ticagrelor monotherapy indefinitely (vs switching to aspirin at 12 months) is superior remains unresolved. Prasugrel monotherapy safety is NOT established post-ACS ≥1 month. (sources/ACS-AHA-2025, rating: very high)
- P2Y12 inhibitor preloading before angiography (NSTE-ACS): Routine preloading not supported by RCT data for early invasive strategy (<24 h); prasugrel pre-loading increases bleeding. PLATO did not separately compare upstream vs at-PCI ticagrelor. May be reasonable for delayed invasive strategy (>24 h). (sources/ACS-AHA-2025, rating: very high)
- De-escalation (guided vs unguided): Guided de-escalation (platelet function assay or CYP2C19 genotyping) has mixed trial evidence — some trials show no benefit over conventional DAPT. Unguided de-escalation trials are more consistently positive for bleeding reduction. (sources/ACS-AHA-2025, rating: very high)
- When to define transition from ACS to chronic coronary syndrome: No RCT data; this affects decisions about DAPT de-escalation or antiplatelet continuation beyond 12 months. (sources/ACS-AHA-2025, rating: very high)
- ACS monotherapy vs CCD extended DAPT discordance: ACS 2025 guideline recommends ticagrelor monotherapy (aspirin drop) at ≥1 month post-PCI as COR 1/A; CCD 2023 guideline supports extended ticagrelor 60 mg BID + aspirin beyond 12 months (COR 2b/A) for prior MI. These represent distinct time points (acute vs chronic phase) but the transition boundary is undefined. (sources/ACS-AHA-2025, sources/CCS-AHA-2023, both rating: very high)
Connections
- Related to entities/Acute-Coronary-Syndrome — ACS post-PCI management
- Related to entities/Chronic-Coronary-Disease — CCD-phase antiplatelet; extended DAPT; rivaroxaban strategy
- Related to entities/Atrial-Fibrillation — triple therapy in ACS + AF; AFIRE in CCD + AF
- Related to concepts/Dyslipidemia-Management — comprehensive secondary prevention in ACS and CCD
- Related to concepts/ASCVD-Risk-Assessment — secondary prevention strategy
- Related to concepts/Perioperative-Cardiovascular-Assessment — perioperative antiplatelet management and PCI timing before NCS
- Related to sources/periop-aha-2024
- Related to entities/Ischemic-Stroke — DAPT for minor AIS/TIA (CHANCE, POINT); ticagrelor+aspirin for LAA etiology (THALES)